Gender as a factor affecting NK cell activity in patients successfully treated for chronic hepatitis C with direct-acting antivirals

被引:2
|
作者
Zientarska, Agata [1 ]
Mikula-Pietrasik, Justyna
Kaczmarek, Mariusz [2 ]
Witkowska, Aleksandra
Rozplochowski, Blazej
Kowala-Piaskowska, Arleta
Ksiazek, Krzysztof
Zeromski, Jan
Mozer-Lisewska, Iwona
机构
[1] Poznan Univ Med Sci, Chair & Dept Infect Dis Hepatol & Acquired Immuno, Poznan, Poland
[2] Poznan Univ Med Sci, Dept Canc Immunol, Poznan, Poland
关键词
HCV; gender; NK cells; direct-acting antivirals; INTERFERON-FREE THERAPY; NATURAL-KILLER-CELLS; VIRUS-INFECTION; RECEPTOR EXPRESSION; SEX; SUSCEPTIBILITY; CYTOTOXICITY; FREQUENCIES; CXCL10; AGE;
D O I
10.5114/ceji.2021.109846
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic hepatitis C (CHC) affects the activity of natural killer (NK) cells, but successful interferonfree treatment partially restores it. The goal of this study was to assess whether gender influences NK functionality. We examined 21 post-menopausal women and 24 men with CHC who were treated with direct-acting antivirals (DAA) and 33 healthy volunteers. Using flow cytometry, we analysed KIR2DS4, NKG2D, NKp30, KIR2DL2/DL3, NKG2A and TRAIL on the surface of NK cells. Intracellular granzyme B was also assessed and serum CXCL10 was quantified via ELISA. Overall, patients with CHC had higher expression of KIR2DS4, NKG2A, and NKp30 relative to the control group. Further, CHC patients had a lower percentage of NK cells among lymphocytes relative to the control group. After treatment, KIR2DS4, KIR2DL2/DL, NKG2A, TRAIL and NKp30 on NK cells were decreased whilst the percentage of NK cells and the expression of granzyme B and NKG2D increase& Prior to treatment, serum CXCL10 was elevated, but it was inhibited post-treatment. We observed gender-specific differences in the expression of KIR2DL2/DL3 (higher in women) and NKp30 (elevated in men) compared to CHC/control groups. After treatment, KIR2DL2/DL3, NKp30 and CXCL10 dropped only in the female group while granzyme B increased in the male group. In conclusion, the response of NK cells among men and women of post-menopausal ages with CHC differs. Our research may lead to more studies on the different nature of female and male immune systems in the context of HCV infection and treatment.
引用
收藏
页码:481 / 491
页数:11
相关论文
共 50 条
  • [31] Targeting Hepatitis C With Direct-Acting Antivirals
    Pennell, Laurie
    LaPreze, Jennifer
    US PHARMACIST, 2023, 48 (02) : HS6 - +
  • [32] Update on hepatitis C: Direct-acting antivirals
    Leon L Seifert
    Ryan B Perumpail
    Aijaz Ahmed
    World Journal of Hepatology, 2015, (28) : 2829 - 2833
  • [33] Direct-acting antivirals: the endgame for hepatitis C?
    D'Ambrosio, Roberta
    Degasperi, Elisabetta
    Colombo, Massimo
    Aghemo, Alessio
    CURRENT OPINION IN VIROLOGY, 2017, 24 : 31 - 37
  • [34] Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
    Iliescu, Elena Laura
    Mercan-Stanciu, Adriana
    Toma, Letitia
    BMC NEPHROLOGY, 2020, 21 (01)
  • [35] Influence of statines in the modifications of lipid and hydrocarboned metabolism in patients with chronic hepatitis C treated with direct-acting antivirals
    Linares, P.
    Alvarez-Cuenllas, B.
    Jorquera, F.
    Quinones, R.
    Reyes, N.
    Molina, G.
    Villar, C.
    Guerra-Gonzalez, M.
    Fernandez-Moran, E.
    Gutierrez-Gutierrez, E.
    Fierro-Gonzalez, D.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S311 - S311
  • [36] Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance
    Jimenez-Perez, Miguel
    Gonzalez-Grande, Rocio
    Espana Contreras, Pilar
    Pinazo Martinez, Isabel
    de la Cruz Lombardo, Jesus
    Olmedo Martin, Raul
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (29) : 6573 - 6581
  • [37] Reduction of liver stiffness by direct-acting antivirals for chronic hepatitis C
    Kawabe, Naoto
    Kan, Toshiki
    Takamura, Tomoki
    Nomura, Sayuri
    Hashimoto, Senju
    Murao, Michihito
    Nakano, Takuji
    Nakaoka, Kazunori
    Ohki, Masashi
    Yuka, Ochi
    Kurashita, Takamitsu
    Fukui, Aiko
    Nishikawa, Toru
    Osakabe, Keisuke
    Ichino, Naohiro
    Yoshioka, Kentaro
    HEPATOLOGY, 2016, 64 : 462A - 462A
  • [38] Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
    Ryu, Ji Eun
    Song, Myeong Jun
    Kim, Seok-Hwan
    Kwon, Jung Hyun
    Yoo, Sun Hong
    Nam, Soon Woo
    Nam, Hee Chul
    Kim, Hee Yeon
    Kim, Chang Wook
    Yang, Hyun
    Bae, Si Hyun
    Song, Do Seon
    Chang, U. Im
    Yang, Jin Mo
    Lee, Sung Won
    Lee, Hae Lim
    Lee, Soon Kyu
    Sung, Pil Soo
    Jang, Jeong Won
    Choi, Jong Young
    Yoon, Seung Kew
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (05): : 958 - 968
  • [39] Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
    Elena Laura Iliescu
    Adriana Mercan-Stanciu
    Letitia Toma
    BMC Nephrology, 21
  • [40] Direct-Acting Antivirals Treatment Effects for Chronic Hepatitis C Patients with Maintenance Dialysis
    Shih, Ming-Huang
    Wu, Feng-Mei
    Kang, I-Ching
    Chang, Chia-Chu
    Chious, Ping-Fang
    NEPHROLOGY NURSING JOURNAL, 2018, 45 (02) : 204 - 204